GRAL Stock Summary and Trading Ideas (Grail | NASDAQ:GRAL)

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Grail trades on the NASDAQ stock market under the symbol GRAL.

As of June 12, 2026, GRAL stock price declined to $59.85 with 337,618 million shares trading.

GRAL has a beta of 2.15, meaning it tends to be more sensitive to market movements. GRAL has a correlation of 0.06 to the broad based SPY ETF.

GRAL has a market cap of $2.57 billion. This is considered a Mid Cap stock.

Last quarter Grail reported $40 million in Revenue and -$2.29 earnings per share. This beat revenue expectation by $415,712 and missed earnings estimates by -$.12.

The top ETF exchange traded funds that GRAL belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWN.

GRAL has outperformed the market in the last year with a return of +42.8%, while the SPY ETF gained +24.1%. In the last 3 month period, GRAL beat the market returning +35.0%, while SPY returned +11.6%. However, in the most recent 2 weeks GRAL has underperformed the stock market by returning -16.5%, while SPY returned -1.9%.

GRAL support price is $56.83 and resistance is $63.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRAL shares will trade within this expected range on the day.